RxDoctor Payments Data

Serge-Henri Gardere, DO

Family Medicine · Wilton Manors, FLNPI 1275838542

Payments from drug & device makers

$8,399in general payments, 2019–2025

Across 422 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$3K
  • Viiv Healthcare Company$3K
  • Johnson & Johnson$560
  • Merck$227
  • EMD Serono, Inc.$203
  • Antares Pharma, Inc.$199
  • plus $989 from 18 others

What the payments were for

  • Food & beverage$8,385100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,399 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$442,103
Medicare patients
136
Services billed
5,365

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala64$262,355
JulucaDolutegravir/Rilpivirine40$140,892
CabenuvaCabotegravir/Rilpivirine21$126,882
OzempicSemaglutide32$39,971
MounjaroTirzepatide21$25,024
IsentressRaltegravir Potassium12$23,579
PifeltroDoravirine11$19,755
EliquisApixaban22$17,198
BotoxOnabotulinumtoxina12$15,516
Etravirine12$13,687
VascepaIcosapent Ethyl12$9,450
AbacavirAbacavir Sulfate12$3,614
Testosterone Cypionate34$2,716
ValacyclovirValacyclovir Hcl16$872
Methylprednisolone92$701

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyJuluca, Cabenuva$2,756$267,77461 claims
GileadBiktarvy$3,465$262,35564 claims
MerckIsentress, Pifeltro$227$43,33423 claims
Lilly USA, LLCMounjaro$83$25,02421 claims
PfizerEliquis$23$17,19822 claims
AbbVieBotox$83$15,51612 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$24$21326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Wilton Manors

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →